$APT

ALPHA PRO TECH LTD (APT): Submission of Matters to a Vote of Security Holders

ALPHA PRO TECH LTD (APT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. apt20260615c_8k.htm false 0000884269 0000884269 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event repo

Original reporting
Published Jun 15, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$APT
Neutral
high confidence
Mentioned
$APT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$APTNeutralLow
01

Why it matters

The disclosure confirms directors were elected, the independent auditor (Tanner LLP) was ratified for FY ending Dec. 31, 2026, and shareholders approved executive compensation on an advisory basis.

02

Market read

This is a routine governance/voting update with no new financial or strategic information.

03

What to watch

The advisory say-on-pay result includes vote counts; however, without management changes or compensation policy details, it is unlikely to drive trading.

Relevance 6/10Novelty 2/10Timing: Filed June 15, 2026 for a June 10, 2026 annual meeting vote

Background

The company’s Form 8-K (Item 5.07) reports final results from its June 10, 2026 annual meeting of shareholders.

Company-level read

Ticker impact

$APTNeutralHigh confidence
Context

Alpha Pro Tech filed an 8-K detailing June 10, 2026 shareholder votes, including director elections and ratification of its auditor for 2026.

Expected impact

Limited near-term impact; any reaction is likely noise unless investors were focused on governance outcomes.

Evidence & confidence

The filing is a standard Item 5.07 disclosure summarizing votes (directors, auditor ratification, advisory say-on-pay) without new operating or financial information.

Market effects

Minimal; governance vote outcomes typically do not reset sector expectations.

Minimal; filing is company-specific and not tied to a regional macro event.

Minimal; no cross-border transaction or regulatory action described.

Counterpoint

If investors were concerned about board composition or auditor continuity, the vote totals could reduce uncertainty, but the filing still lacks any new catalyst.

Key entities

  • Alpha Pro Tech, Ltd.

    Subject of the SEC 8-K; reports annual meeting voting outcomes.

  • Tanner LLP

    Independent registered public accounting firm ratified for the fiscal year ending Dec. 31, 2026.

Related articles

$APTMed

ALPHA PRO TECH, LTD. ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

ALPHA PRO TECH LTD (APT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ALPHA PRO TECH, LTD. ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Second Quarter Net Sales Increased by 12% to $18.7 Million from $16.7 Million in the Second Quarter of 2025; Second Quarter Net Income Increased by 47% to $1.8 Million from $1.2 Million in the Prior

$RIOMed

Rio Tinto eyes $A7b capital release, iron ore sales up

Rio Tinto reported a 2% increase in Pilbara iron ore sales to 85.7 million tonnes, exceeding estimates. The company aims to release $7.2 billion in capital by 2026, with $2 billion already released this year. Copper output remained flat, and lithium production is expected at the lower end of forecasts. Iron ore sales for 2026 are forecasted between 323-338 million tonnes.

$SNYMed

Korea health agency lets Sanofi cut NIP flu supply, igniting favoritism furor

Sanofi-Aventis Korea reduced its National Immunization Program (NIP) flu vaccine supply from 2.25M to 1.75M doses due to production disruptions. The Korea Disease Control and Prevention Agency amended the contract without penalties, allowing Sanofi to divert 500,000 doses to the higher-priced private market. Critics argue this favors Sanofi and may disrupt supply for domestic firms like GCGC Biopharma (006280).